← Back to Search
Control Of Cell Proliferation By Myc Proteins.
A. Bürgin, C. Bouchard, M. Eilers
Published 1998 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Taken together, the available data appear to be consistent with a model in which Myc proteins function downstream of D-type cyclins and synergize with E2F proteins in the activation of the cyclin E/cdk2 kinase. This view of Myc proteins appears strikingly similar to established models for the E2F/DP family of proteins. However, it should be noted that there are clear differences and several predictions of such a model that have been critically tested for E2F proteins are still untested for Myc in this model. First, it appears that at least some target genes of Myc implicated in this process are still unknown; second, clear data from knockout cells that link p107 to Myc function are missing; and third, we are not aware of studies of tumour samples that clarify whether mutations in myc genes relieve the requirement for mutations in the cyclin D/p16 pathway.
This paper references
c‐Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II.
L. Li (1994)
Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation.
K. Galaktionov (1995)
c‐Myc‐induced apoptosis in fibroblasts is inhibited by specific cytokines.
E. A. Harrington (1994)
Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
Lelia Alland (1997)
Loss of Rb and Myc activation co-operate to suppress cyclin D1 and contribute to transformation.
W. Marhin (1996)
Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis.
G. Packham (1994)
end5, end6, and end7: mutations that cause actin delocalization and block the internalization step of endocytosis in Saccharomyces cerevisiae.
A. Munn (1995)
Binding and suppression of the Myc transcriptional activation domain by p107.
W. Gu (1994)
BIN1 is a novel MYC–interacting protein with features of a tumour suppressor
D. Sakamuro (1996)
An essential domain of the c-myc protein interacts with a nuclear factor that is also required for E1A-mediated transformation.
D. Brough (1995)
Growth arrest by the cyclin‐dependent kinase inhibitor p27Kip1 is abrogated by c‐Myc.
J. Vlach (1996)
Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells
M. Eilers (1989)
Max: functional domains and interaction with c-Myc.
G. Kato (1992)
Activation of cyclin‐dependent kinases by Myc mediates induction of cyclin A, but not apoptosis.
B. Rudolph (1996)
Identification of a Myc‐dependent step during the formation of active G1 cyclin‐cdk complexes.
P. Steiner (1995)
Activation of c-Myc uncouples DNA replication from activation of G1-cyclin-dependent kinases
O. Pusch (1997)
Reciprocal Regulation of Adipogenesis by Myc and C/EBPα
S. Freytag (1992)
Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
P. Hurlin (1997)
Cdc25 cell-cycle phosphatase as a target of c-myc
K. Galaktionov (1996)
Interaction of c‐Myc with the pRb‐related protein p107 results in inhibition of c‐Myc‐mediated transactivation.
R. Beijersbergen (1994)
Inhibition of cell proliferation by the Mad1 transcriptional repressor.
M. Roussel (1996)
Binding of myc proteins to canonical and noncanonical DNA sequences.
T. Blackwell (1993)
The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice
W. Langdon (1986)
Mad-max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3
D. Ayer (1995)
Burkitt-like mutations in the c-myc gene locus in prolymphocytic leukemia.
U. Brennscheidt (1994)
The c‐Myc protein induces cell cycle progression and apoptosis through dimerization with Max.
B. Amati (1993)
Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle
A. Koff (1992)
Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor
K. Kelly (1983)
An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants.
R. Miltenberger (1995)
Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression
Carol D. Laherty (1997)
Identification of the human c-myc protein nuclear translocation signal.
C. V. Dang (1988)
An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc.
R. Jones (1996)
Point mutations in the c–Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas
K. Bhatia (1993)
Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells.
G. Inghirami (1990)
Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity
D. Ayer (1993)
Oncogenic activity of the c-Myc protein requires dimerization with Max
B. Amati (1993)
Characterization of a new gene family developing pleiotropic phenotypes upon mutation in Saccharomyces cerevisiae.
E. Revardel (1995)
Differential modulation of cyclin gene expression by MYC.
P. Jansen-Dürr (1993)
Ligands for ErbB-family receptors encoded by a neuregulin-like gene
Han Chang (1997)
Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity
K. Berns (1997)
G1 phase progression: Cycling on cue
C. Sherr (1994)
The ornithine decarboxylase gene is a transcriptional target of c-Myc.
C. Bello-Fernandez (1993)
E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions.
F. Oswald (1994)
Regulation of cyclin E transcription by E2Fs and retinoblastoma protein.
Y. Geng (1996)
A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1
R. Heikkila (1987)
Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc.
L. Desbarats (1996)
Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling
M. F. Roussel (1991)
An amino-terminal c-myc domain required for neoplastic transformation activates transcription.
G. Kato (1990)
Expression of mad, mxi1, max and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc.
L. Larsson (1994)
Cyclin E and c‐Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins
K. Alevizopoulos (1997)
Autoimmunity in Stiff‐Man Syndrome with breast cancer is targeted to the C‐terminal region of human amphiphysin, a protein similar to the yeast proteins, Rvs167 and Rvs161
C. David (1994)
Mad3 and Mad4: novel Max‐interacting transcriptional repressors that suppress c‐myc dependent transformation and are expressed during neural and epidermal differentiation.
P. Hurlin (1995)
The MYC protein activates transcription of the alpha‐prothymosin gene.
M. Eilers (1991)
Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter.
J. Botz (1996)
Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation.
H. Lovec (1994)
Inducible regulatory elements in the human cyclin D1 promoter.
B. Herber (1994)
Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment
J. Coppola (1986)
Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes
D. Müller (1997)
The Myc:Max protein complex and cell growth regulation.
E. Blackwood (1991)
Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2.
A. Wagner (1993)
Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites
A. Zervos (1993)
Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27Kip1 binding to newly formed complexes
I. Pérez-Roger (1997)
Mediation of c-Myc-induced apoptosis by p53.
H. Hermeking (1994)
Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1.
S. Freytag (1988)
Definition of regions in human c-myc that are involved in transformation and nuclear localization.
J. Stone (1987)
Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity
A. Sommer (1997)
Repression of cyclin D1: a novel function of MYC.
A. Philipp (1994)
Myc and Max Homologs in Drosophila
P. Gallant (1996)
The regulation and expression of c-myc in normal and malignant cells.
K. Kelly (1986)
Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.
A. Wagner (1994)
Signaling by ABL oncogenes through cyclin D1.
D. Afar (1995)
A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation.
D. Ayer (1993)
A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice.
A. Davis (1993)
Proteins of the Myc network: essential regulators of cell growth and differentiation.
M. Henriksson (1996)
Fibroblast lines expressing activated c-myc oncogenes are tumorigenic in nude mice and syngeneic animals
E. Keath (1984)
Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression.
S. Langer (1992)
c-myc inhibition of MyoD and myogenin-initiated myogenic differentiation.
J. Miner (1991)
Rescue of defective mitogenic signaling by D-type cyclins.
M. Roussel (1995)
Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation
G. Prendergast (1991)
Direct role for Myc in transcription initiation mediated by interactions with TFII-I
A. Roy (1993)
Induction of apoptosis in fibroblasts by c-myc protein
G. Evan (1992)
Negative autoregulation of c‐myc transcription.
L. Penn (1990)
Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
M. Roussel (1994)
Mutual requirement of CDK4 and Myc in malignant transformation: evidence for cyclin D1/CDK4 and p16INK4A as upstream regulators of Myc
K. Haas (1997)
An amino-terminal domain of Mxi1 mediates anti-myc oncogenic activity and interacts with a homolog of the Yeast Transcriptional Repressor SIN3
N. Schreiber-Agus (1995)
Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc.
A. Shrivastava (1993)
Phorbol ester-induced terminal differentiation is inhibited in human U-937 monoblastic cells expressing a v-myc oncogene.
L. Larsson (1988)
Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src
M. Barone (1995)
Myc and Max associate in vivo.
E. Blackwood (1992)
Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection.
T. Blackwell (1990)
This paper is referenced by
Targets for Molecular Intervention in Multistep Pulmonary Carcinogenesis
M. D. David S. Schrump (2001)
Targets for Molecular Intervention in Multistep Pulmonary Carcinogenesis
M. D. D. S. Schrump (2001)
K-RAS point mutation, and amplification of C-MYC and C-ERBB2 in colon adenocarcinoma.
W. Kruszewski (2004)
The 400 kDa subunit of the PCAF histone acetylase complex belongs to the ATM superfamily.
A. Vassilev (1998)
The interplay between MYC and HIF in the Warburg effect.
C. V. Dang (2007)
Receptors, Signaling Pathways, Cell Cycle, and DNA Damage Repair
P. Cagle (2009)
Molecular genetics of lung and pleural neoplasms
P. Cagle (2008)
The basic region/helix – loop – helix/leucine zipper domain of Myc proto-oncoproteins: Function and regulation
B. Lüscher (1999)
Dermatopontin inhibits papillary thyroid cancer cell proliferation through MYC repression
Y. Guo (2019)
Bringing order to disorder : structural and functional analysis for development of strategies to target myc
I. Müller (2014)
Global Regulation of Nucleotide Biosynthetic Genes by c-Myc
Y. Liu (2008)